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Background: Induced sputum (IS) is feasible and safe in young CF children and is a readily accessible, non-invasive technique. However, it has not
been compared to bronchoalveolar lavage (BAL), the gold standard for diagnosing lower airway infection.
Methods:We compared bacterial yield from IS and BAL in 11 non-expectorating CF children, aged 3 to 7.4 years. IS samples were obtained in 10/
11 cases.
Results: Eight out of ten had the same predominant bacteria cultured from IS and BAL: Pseudomonas aeruginosa and Stenotrophomonas
maltophilia [1], Staphylococcus aureus [3], and upper respiratory tract ﬂora [4]. In one, Serratia marcescens and Haemophilus parainfluenzae
were cultured from IS alone, whereas in one, non-group B Haemophilus influenzae was cultured from BAL alone.
Conclusions: As proof of principle, IS samples showed good bacteriologic correlation with BAL. Larger studies are recommended to conﬁrm IS as
a clinically valuable tool and measure for early intervention studies in young CF children.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Bronchoalveolar lavage; Induced sputum; Infants1. Introduction
Chronic infection and inflammation play a central role in the
life-shortening lung disease of cystic fibrosis (CF), beginningAbbreviations: BAL, bronchoalveolar lavage; CF, cystic fibrosis; IS, induced
sputum; URTF, upper respiratory tract flora; P. aeruginosa, Pseudomonas
aeruginosa; S. aureus, Staphylococcus aureus; H. influenzae, Haemophilus
influenzae; S. marcescens, Serratia marcescens.
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http://dx.doi.org/10.1016/j.jcf.2013.05.013in the first few months of life and often silent [1]. Severe,
neutrophilic inflammation that leads to bronchiectasis and,
eventually, respiratory failure and death, has been identified as
early as two months of age in association with early bacterial
and viral infections [2].
Bronchoalveolar lavage (BAL) remains the “gold standard”
for defining airway microbiology and inflammation in young
children [3], but has important limitations. It is invasive,
requires anesthesia, consumes time and resources and is costly.
Furthermore, IS can be more readily repeated within the routine
CF clinic visit, to determine if, for example, Pseudomonas
aeruginosa has been successfully eradicated following an
initial positive BAL or IS culture. BAL often samples only
one or two segments of the lung, limiting detection of infection.by Elsevier B.V. All rights reserved.
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Fibrosis (AREST CF) demonstrated that structural lung disease
begins in the first few months of life [4] and before the median
age of 30.5 months when infection with P. aeruginosa was
detected [5]. Infections with bacteria such as Staphylococcus
aureus (S. aureus) and non-typeable Haemophilus influenzae
are more prevalent during early childhood. Focus in particular on
S. aureus is increasing, as it is associated with poorer nutritional
outcomes [6], decline in lung function [7] and bronchiectasis [8]
as well as having an impact on CF inflammation and clinical
outcomes [9].
Therefore, there is an urgent need for repeated, non-invasive
measures of infection and inflammation for young children
with CF in order to impact on development of lung disease.
Induced sputum (IS) using hypertonic saline inhalation in
expectorating children and adults is a safe, simple, non-invasive
and repeatable diagnostic tool for obtaining secretions pooled
from the lower airways [9].
Lower respiratory sampling is required to distinguish lower
airway infection from upper airway colonization and therefore
more appropriately target treatment. We have demonstrated
safety and feasibility of IS previously in young children, with a
superior bacteriologic yield compared to cough swabs [10]. To
date, however, there have been no studies comparing IS to BAL
for bacteriologic yield in young, non-expectorating children with
CF.We therefore embarked on a pilot study to compare these two
procedures, within a cohort of young non-expectorating children
with CF.
2. Methods
We enrolled non-expectorating children with a confirmed
diagnosis of CF, treated at the CF center at the Royal Children's
Hospital, Melbourne, who were undergoing BAL, either as
part of an “Early Surveillance Program” that included annual
assessments of BAL, CT and infant lung function [2,6–8], as
part of the Australasian Cystic Fibrosis Bronchoalveolar Lavage
(ACFBAL) study [4], or if clinically indicated for microbiologic
diagnosis. This amalgamation of subjects included both stableTable 1
Patient induced sputum collection details.
Patient no. Age (y) Cough amount Cough quality a O2 sat. pre O
1 4.24 None Dry 99 99
2 4.19 Moderate Productive 96 95
3 4.04 None Dry 99 99
4 4.98 None Dry 98 97
5 5.3 Moderate Productive 99 98
6 5.08 Moderate Productive 98 96
7 5.19 None Dry 99 99
8 7.44 Mild Productive 98 98
9 4.03 Mild Productive 99 99
10 3.02 Moderate Dry 98 98
Physiotherapy type: 1 = bubble PEP, 2 = trampoline, 3 = exercise under supervisio
a Cough productivity was assessed subjectively by the physiotherapist prior to or
b ‘Distressed’: crying and resisting somewhat.
c ‘Very distressed’: crying and resisting a lot (as seen during taking blood tests inand acutely sick children, making the study population quite
heterogenous. However, in all of these subjects, comparison
of BAL and IS yields is of major importance. As BAL is
an invasive procedure, we chose children who were already
undergoing the procedure, as the subjects for this comparative
pilot study. A sub-group of these children who lived in proximity
to the hospital and agreed to come in for a separate visit in order
to undergo an IS procedure, was selected to have an IS specimen
taken on a single occasion for microbiological study. These
children were selected consecutively from the potential study
population.
Specimens of IS were taken in the CF clinic, 1–13 days after
the BAL in order not to influence parameters of inflammation
as described previously [11]. No change in antibiotic therapy
occurred between samples.
Children were pre-treated with two puffs of salbutamol,
100 μg/puff, using a spacer device with mask, followed by an
inhalation of 10 cc of 4.5% saline solution via an ultrasonic
nebulizer for 10 min. Physiotherapy, adapted to the individual,
was then performed to mobilize secretions (Table 1). Oropha-
ryngeal suction was performed with a size 10 catheter connected
to a sterile mucus extractor to obtain a clearly visualized
specimen of sputum. Sputum and BALwere cultured by standard
procedures in the clinical microbiology laboratory of the Royal
Children's Hospital, using 104 cfu/mL to determine a positive
culture. Sputum clumps were dispersed mechanically, using
sterile glass beads [12].
The study was approved by the Royal Children's Hospital
Ethics in Human Research Committee (EHRC) ref. no. 25054
and parents of participants signed informed consent forms in
each case.3. Results
Eleven children, aged 3.0 to 7.4 years, participated in the
study. The details of the IS procedure are shown in Table 1. The
entire procedure took between 20 and 45 min, including
inhalation of salbutamol and hypertonic saline, physiotherapy2 sat. post Type physio Procedure time (min) Subjective experience
2 45 Tolerated fairly well
3 30 Tolerated fairly well
2 40 Tolerated well
1, 2 45 Distressed b
2 45 Distressed b
2 35 Tolerated fairly well
1 20 Tolerated fairly well
1 30 Tolerated fairly well
3 25 Tolerated well
1, 3 30 Very distressed c
n.
during physiotherapy.
some young children).
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There was no change in oxygen saturation during suction.
Of the 11 subjects participating, 10 succeeded in providing a
sample of induced sputum (Table 2). There was no relationship
between cough productivity (as described in Table 1) and
microbiologic yield of the IS procedure, as patients with dry
cough often had IS cultures which were positive for bacteria. Of
the 10 specimens collected, 8 had the same predominant bacteria
cultured from both the IS and the BAL specimens with identical
bacteria sensitivity profiles. Table 2 also indicates whether the
bacteria cultured were scant, moderate or profuse in quantity.
Where present, upper respiratory tract flora (URTF) was scant
in BAL and profuse in IS cultures. There was no correlation
between BAL and IS regarding culture ofAspergillus orCandida.
Candida was present in two IS specimens and one other BALTable 2
Microbiology findings of BAL and induced sputum specimens.
Patient
no.
Age
(y)
Between
BAL & IS (d)
Patient
group
Microbiology
BAL
Microorganism Antimicrobial
1 4.24 13 AREST URTF + n/a
2 4.19 12 AREST S. aureus +
mixed neg.
bacilli +
S. aureus:
pen-s, clindam
vanco-s, erythr
flucox-s, and te
3 4.04 5 AREST No bacterial growth n/a
4 4.98 6 ACFBAL P. aeruginosa +++
S. maltophilia +++
A. fumigatis +
P.aeruginosa:
tobra-s, cipro-s
amik-s, piper-s
norflox-s, tim-
and aztreonam
S. Maltophilia:
cotrimoxazole-
5 5.3 8 ACFBAL URTF ++ n/a
6 5.08 5 ACFBAL S. aureus +++
URTF ++
S.aureus: pen-r
vanco-s, erythr
and teicoplanin
7 5.19 9 ACFBAL URTF + n/a
8 7.44 1 Clinical MRSA +++
C. glabrata +
S.aureus: pen-r
vanco-s, erythr
and teicoplanin
9 4.03 6 AREST URTF + n/a
10 3.02 4 AREST H. influenza
(not type b)
Ampicillin-r,
augmentin-s,
cefotaxime-s, a
Bacterial growth: + = scant, ++ = moderate, +++ = profuse; BAL = bronchoalveo
Early Surveillance Team for Cystic Fibrosis’, an early surveillance program study
Clinical = BAL was done for clinical diagnostic purposes.
d = days; URTF — upper respiratory tract flora; MRSA = methicillin resistant S. a
Sensitivity to antibiotics: pen = penicillin; vanco = vancomycin; erythro = erythrom
gentamicin; ceftaz = ceftazidime; amik = amikacin; piper = piperacillin; norflox = nospecimen whereas Aspergillus was found in one BAL but not in
the corresponding IS.
4. Discussion
In this pilot study we have confirmed the feasibility and safety
of IS in non-expectorating children with CF and compared results
from IS with those from BAL. IS samples provided a similar
microbiologic yield to BAL procedures as proof of principle,
although the study was underpowered for formal statistical
analysis.
Although we aimed to perform IS within a week of BAL,
this was not always feasible for logistic reasons, as parents
could not bring the child in for earlier IS. Fortunately, antibiotic
therapy remained the same in all cases during this period. It wasIS
susceptibility Microorganism Antimicrobial susceptibility
URTF +++ n/a
ycin-s,
o-s,
icoplanin-s
S. aureus +++ S. aureus:
pen-r, clindamycin-s,
vanco-s, erythro-s,
flucox-s, and teicoplanin-s
S. marcescens +
H. parainf ++
URTF
S. marcescens:
ampicillin-r,
cephalothin-r,
cefotaxime-s,
gentamicin-s,
ceftazidime-s,
augmentin-r,
cotrimoxazole-s,
cefpodoximer-I, tobra-s and cipro-s
genta-s, ceftaz-s,
, meropenem-s
, cefipime-s,
s, pip/tazobactam-s,
-s
s
P. aeruginosa +
S. maltophilia +
P.aeruginosa: genta-s, ceftaz-s,
tobra-s, cipro-s, meropenem-s amik-s,
piper-s, cefipime-s, norflox-s, tim-s,
pip/tazobactam-s, and aztreonam-s
S. Maltophilia:
cotrimoxazole-s
URTF +
C. albicans ++
n/a
, clindamycin-s,
o-s, flucox-s,
-s
S. aureus ++
URTF +++
C. albicans +
S.aureus: pen-r, clindamycin-s,
vanco-s, erythro-s, flucox-s,
and teicoplanin-s
URTF +++ n/a
, clindamycin-r,
o-r, flucox-r,
-s
MRSA +++ S.aureus: pen-r, clindamycin-r,
vanco-s, erythro-r, flucox-r,
and teicoplanin-s
URTF +++ n/a
nd cotrimoxazole-r
URTF +++ n/a
lar lavage; IS = induced sputum; y = years; AREST = ‘Australian Respiratory
; ACFBAL = the Australasian Cystic Fibrosis Bronchoalveolar Lavage study;
ureus.
ycin; flucox = flucloxacillin; tobra = tobramycin; cipro = ciprofloxacin; genta =
rfloxacillin; tim = timentin; and pip/tazobactam = piperacillin/tazobactam.
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and IS remained the same in 8 of 10 cases.
In older patients with CF, IS provides an accurate measure of
infection and inflammation [9], with improvement demonstrated
following therapy with intravenous antibiotics [13]. In young CF
children who are able to expectorate only following hypertonic
saline inhalation, IS yielded similar evidence for inflammation
and infection as that from spontaneously expectorating children
[14]. In this group, as well as in our previous study [10], the
microbiological yield increased compared to that with spontane-
ously expectorated sputum or oropharyngeal cough swabs. We
therefore did not include a comparison to oropharyngeal cough
swabs, which would have made the experience more traumatic.
The higher prevalence and more profuse growth of URTF
in IS compared to BAL suggests that IS is more likely to be
contaminated by upper airway secretions than BAL specimens.
However, as both types of sampling often contain upper airway
flora, we do not believe this negates the utility of IS.
Recently, the diversity of organisms that constitute the lower
respiratory microbiota, including the identification of species
found commonly in the upper respiratory tract, has been
described [15]. Thus, in the present study, it is possible that
these organisms are present in the lower respiratory secretions
and may not necessarily be indicative of contamination from
the upper airways. Importantly, in one case, H. influenza was
identified by BAL alone. This suggests that in children with
significant clinical disease where IS does not identify a
bacteria, BAL should still be considered a diagnostic option,
especially if there is no improvement with empiric antibiotic
therapy.
The IS procedure can be distressful. Although most children
tolerated it fairly well (Table 1) and did not cry or show upset, one
child was severely distressed, crying and resisting the procedure.
The main unpleasant element during IS is the actual suction
procedure, which lasts only 1–2 min. This is similar to blood
tests and other common procedures, which are often distressing,
and resisted physically by very young children. However, this
brief distress should be balanced by the importance of the
bacteriologic diagnosis enabling appropriate antibiotic therapy.
Reliable detection of bacterial pathogens depends upon the
frequency of cultures obtained [16]. In our center (SCMCI), IS in
non-expectorating infants with CF is now routinely performed,
about 4–6 times per year, enabling early detection, treatment and
ascertainment of eradication of infections, which would not be
possible with BAL. Recently, we have developed interventions
which make the IS much less stressful, by providing calm
surroundings and distraction for the child.
The validity and safety of IS for bacteriologic diagnosis in
infants have been demonstrated in other populations. Two large
studies in infants showed IS testing to be safe and useful for
diagnosing Pneumocystis jirovecii [17], and demonstrated a
higher yield for tuberculosis than gastric lavage [18]. Several
studies have shown that even a 7% hypertonic saline inhalation
solution can be used safely as a therapeutic agent in infants
[19,20].
The recent evidence for the role of S aureus in the
development of lung disease in CF [6–8], means that improvedsurveillance and treatment of infection with this organism is
indicated. Better targeting of therapy is required in order to
improve the benefit: risk ratio of such treatment. The results
from our pilot study suggest that the technique of IS may have
such a role, especially in those centers where BAL is not feasible.
Further studies are required to establish the role of IS to detect
lower respiratory infection with S aureus, P. aeruginosa and
other organisms in infants with CF and the reliability of IS culture
for bacteria and assay of inflammatory markers, both for clinical
practice decisions and as surrogate outcome measures for
interventional studies in young children with CF.References
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